IL6 and cervical carcinoma: For instance, IL-6 blockade via monoclonal antibodies or JAK/STAT3 inhibitors has demonstrated early promise in solid tumors, including cervical cancer, by reducing proliferation, reversing EMT, and sensitizing tumor cells to chemotherapy and radiotherapy.